MENU

CSL clinical studies prove successful

CSL (ASX: CSL) has a long and proud history of developing therapies to improve patients’ lives. This week CSL announced  promising results from “clinical studies involving a new group of therapies for the treatment of haemophilia”.

One of the beauties of CSL’s business model has been the company’s ability to innovate therapies, through research and development, which improve upon and expand upon its current sales base. CSL has for many years provided blood plasma products to treat hemophilia  so news of a potential new therapy for bleeding disorders (including hemophilia) and the associated development have low business risks given CSL already knows the market well and services it extensively.

Another firm which also has a similarly low-risk business model is implantable hearing device company Cochlear (ASX: COH). Cochlear is continually innovating improvements to its products, which effectively value adds to its current customer base.

The quality of these two firms’ business models has been reflected in their share prices, with CSL and Cochlear up 84% and 37% respectively over the past five years. In comparison the S&P/ASX 200 Index (Index: ^AXJO) (ASX: XJO) is down around 4% over the same period.

In the market for high-yielding ASX shares? Get “3 Stocks for the Great Dividend Boom” in our special FREE report. Click here now to find out the names, stock symbols, and full research for our three favourite income ideas, all completely free!

More reading


Motley Fool contributor Tim McArthur does not own shares in any of the companies mentioned in this article.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.